6640--Lab - Cepheid PCR Molecular Testing
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA) has awarded a sole-source, firm-fixed-price contract to Cepheid for PCR Molecular Testing equipment, reagents, and services. This 6-month contract, valued at $1,133,349.87, ensures the continuity of critical laboratory diagnostic services at multiple VA medical facilities. The award was made on April 2, 2026, following a Notice of Intent to Award Sole Source.
Scope of Work
This contract covers the continued provision of:
- Cepheid GeneXpert and Infinity instruments.
- Molecular reagent kits for various tests, including MRSA, C.difficile, Influenza A/B, RSV, Chlamydia trachomatis/Neisseria gonorrhea, Mycobacterium tuberculosis complex, Streptococcus pyogenes, Trichomonas Vaginalis, Carbapenemase-producing organism identification, and MRSA/SA blood culture identification.
- Necessary equipment, reagents, standards, controls, supplies, consumables, parts, accessories, and cabinets.
- Lease and preventative maintenance services for the instruments.
Contract & Timeline
- Type: Firm-Fixed-Price, Sole Source
- Award Number: 36C24226P0519
- Value: $1,133,349.87
- Period of Performance: April 1, 2026, through September 30, 2026 (6 months)
- Award Date: April 2, 2026
- Set-Aside: None (Sole Source Justification under FAR 12.201-1)
- NAICS Code: 334516
- Product Service Code: 6640 (Laboratory Equipment And Supplies)
Evaluation
This was a sole-source award based on the determination that Cepheid is the only responsible source capable of meeting the agency's requirements without interruption of critical services. Market research indicated no viable small business set-aside opportunities. While a Notice of Intent was issued, this was not a request for proposals or quotations, and no contract award was made based on responses to that notice.
Additional Notes
The sole-source justification highlights Cepheid as the sole provider of compatible equipment and supplies for the VA's existing molecular diagnostic testing infrastructure. This bridge contract is in place to avoid service interruption while a new long-term contract is under development. Interested parties who believed they could provide comparable services were asked to submit their capabilities by March 12, 2026, to inform future competitive procurements.